FLT1 and neoplasm: VEGFR-1 involvement in the induction of the angiogenic switch during pathological conditions, mobilization of precursor stem cells from the bone marrow and tumor growth and migration [4] supports the hypothesis of the therapeutic efficacy of targeting this receptor.